Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-8190
- Development stage
- Preclinical
- Lead developer
- Vir Biotechnology
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
VIR-8190 is an investigational dual specificity human IgG1 monoclonal antibody that potently neutralizes both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) strains. These viruses are significant causes of lower respiratory tract disease, particularly in high-risk populations such as infants and immunocompromised individuals. VIR-8190 was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform and targets the F, Fusion glycoprotein F0, a key viral protein involved in viral entry[1][2][3][6][8][10].
02
Targets
HMPV F (Human metapneumovirus fusion protein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on VIR-8190.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-8190.